U.S. Legislation Passed to Promote Research and Awareness of Scleroderma PDF Print E-mail
Saturday, 02 October 2010 00:50
The Scleroderma Foundation (U.S.) has applauded the U.S. House of Representatives for the passage of the Scleroderma Research and Awareness Act (H.R. 2408), introduced last March by Rep. Lois Capps (D-CA) and Rep. Vern Ehlers (R-MI). This bipartisan legislation gives hope to the estimated 300,000 Americans and their families living with this devastating disease.

The "Scleroderma Research and Awareness Act" will:
Direct the National Institutes of Health to intensify and coordinate activities relating to scleroderma, including:
  • Research on etiology and the development of new treatments.
  • Evaluate new treatments through clinical trials.
  • Research on the relationship between scleroderma and secondary conditions including: pulmonary hypertension, gastroparesis, Raynaud's phenomenon and Sjorgen's syndrome
  • Support for the training of new investigators
Direct the Centers for Disease Control and Prevention to establish a scleroderma public awareness campaign highlighting disease symptoms, prevalence, related conditions, and the importance of early diagnosis.

"The Scleroderma Foundation is proud to be in the forefront of advocating for greater research for this devastating disease," commented Joseph P. Camerino, Ph.D., Chair of the Foundation's National Board of Directors. "With the passage of this landmark legislation, the scleroderma community has even greater hope that a cure will be found."

For further information, please visit the source article here.
 
More articles :

» Simple Predictor In Scleroderma Related Interstitial Lung Disease

Patients at high risk of deterioration or death from Systemic Sclerosis-related interstitial lung disease can be readily spotted using CT scans, suggest Melbourne researchers.Patients classified as having “extensive” (> 20%) lung disease as...

» Donating Kidney Doesn't Shorten Lifespan

A study of over 80,000 American live kidney donors found they were likely to live just as long as people who have two healthy kidneys and that the procedure carries very little medical risk.You can read about the by lead author and transplant...

» A New Marker of Silent Cardiovascular Disease in Diffuse Scleroderma

Patients with diffuse systemic sclerosis (SSc) and no clinical evidence of (CVD) may, in fact, have subclinical CVD and , and it is detectable. This is the conclusion of a small pilot study from Italy, which showed that elevated plasma levels of ...

» Researchers Receive NIH Grant To Study Autoimmune Lung Disease

Researchers at the University of Cincinnati Interstitial Lung Disease Center have received a grant from the National Heart, Lung and Blood Institute to study ways ILD first appears in certain patient groups with autoimmune diseases and how to more...

» Capillary Regeneration in Scleroderma: Stem Cell Therapy Reverses Phenotype?

Jo N. Fleming, Richard A. Nash, D. O. McLeod, David F. Fiorentino, Howard M. Shulman, M. Kari Connolly, Jerry A. Molitor, GretchenHenstorf, Robert Lafyatis, David K. Pritchard, Lawrence D. Adams, Daniel E. Furst, Stephen M....

» New Genetic Path Targeted For Scleroderma Therapy

A genetic pathway previously known for its role in embryonic development and cancer has been identified as a target for systemic sclerosis, or scleroderma, therapy. The finding, discovered by a cross-disciplinary team led by John Varga, MD, John and...